New Risk • May 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (55% net debt to equity). Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (5.6% net profit margin). Reported Earnings • May 18
Second quarter 2026 earnings released: EPS: JP¥8.33 (vs JP¥13.77 in 2Q 2025) Second quarter 2026 results: EPS: JP¥8.33 (down from JP¥13.77 in 2Q 2025). Revenue: JP¥12.7b (up 5.1% from 2Q 2025). Net income: JP¥815.0m (down 39% from 2Q 2025). Profit margin: 6.4% (down from 11% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Declared Dividend • May 16
Dividend of JP¥4.00 announced Dividend of JP¥4.00 is the same as last year. Ex-date: 29th September 2026 Payment date: 22nd December 2026 Dividend yield will be 1.1%, which is lower than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (11% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 32% per year over the past 6 years and payments have been stable during that time. EPS is expected to grow by 6.1% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • May 15
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 28% to JP¥360. The fair value is estimated to be JP¥461, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has declined by 7.4%. For the next 3 years, revenue is forecast to grow by 8.1% per annum. Earnings are also forecast to grow by 2.0% per annum over the same time period. Announcement • Apr 01
Amvis Holdings, Inc. to Report Q2, 2026 Results on May 14, 2026 Amvis Holdings, Inc. announced that they will report Q2, 2026 results at 4:00 PM, Tokyo Standard Time on May 14, 2026 Major Estimate Revision • Mar 08
Consensus EPS estimates increase by 11% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from JP¥25.68 to JP¥28.54. Revenue forecast steady at JP¥52.7b. Net income forecast to shrink 15% next year vs 8.0% growth forecast for Healthcare industry in Japan . Consensus price target down from JP¥601 to JP¥481. Share price fell 4.2% to JP¥500 over the past week. Reported Earnings • Feb 14
First quarter 2026 earnings released: EPS: JP¥11.08 (vs JP¥13.78 in 1Q 2025) First quarter 2026 results: EPS: JP¥11.08 (down from JP¥13.78 in 1Q 2025). Revenue: JP¥12.9b (up 9.9% from 1Q 2025). Net income: JP¥1.08b (down 20% from 1Q 2025). Profit margin: 8.4% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Announcement • Dec 27
Amvis Holdings, Inc. to Report Q1, 2026 Results on Feb 05, 2026 Amvis Holdings, Inc. announced that they will report Q1, 2026 results on Feb 05, 2026 Announcement • Nov 06
Amvis Holdings, Inc., Annual General Meeting, Dec 19, 2025 Amvis Holdings, Inc., Annual General Meeting, Dec 19, 2025. Reported Earnings • Oct 19
Third quarter 2025 earnings released: EPS: JP¥3.18 (vs JP¥19.84 in 3Q 2024) Third quarter 2025 results: EPS: JP¥3.18 (down from JP¥19.84 in 3Q 2024). Revenue: JP¥12.5b (up 13% from 3Q 2024). Net income: JP¥310.0m (down 84% from 3Q 2024). Profit margin: 2.5% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Announcement • Oct 17
Amvis Holdings, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025 Amvis Holdings, Inc. revised consolidated earnings guidance for the fiscal year ending September 30, 2025. For the year, the company expects net sales of JPY 49,100 million, operating profit of JPY 6,100 million, profit attributable to owners of parent of JPY 3,600 million and Earnings per Share of JPY 36.91 compared to previously expected net sales of JPY 53,647 million, operating profit of JPY 8,627 million, profit attributable to owners of parent of JPY 5,804 million and Earnings per Share of JPY 59.30. Announcement • Sep 27
Amvis Holdings, Inc. to Report Fiscal Year 2025 Results on Nov 06, 2025 Amvis Holdings, Inc. announced that they will report fiscal year 2025 results on Nov 06, 2025 Upcoming Dividend • Sep 22
Upcoming dividend of JP¥4.00 per share Eligible shareholders must have bought the stock before 29 September 2025. Payment date: 23 December 2025. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.6%). Announcement • Sep 09
Amvis Holdings, Inc. to Report Q3, 2025 Results on Oct 17, 2025 Amvis Holdings, Inc. announced that they will report Q3, 2025 results on Oct 17, 2025 Reported Earnings • Aug 15
Second quarter 2025 earnings released: EPS: JP¥13.77 (vs JP¥20.17 in 2Q 2024) Second quarter 2025 results: EPS: JP¥13.77 (down from JP¥20.17 in 2Q 2024). Revenue: JP¥12.0b (up 20% from 2Q 2024). Net income: JP¥1.34b (down 32% from 2Q 2024). Profit margin: 11% (down from 20% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 4.6% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to JP¥625, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 13x in the Healthcare industry in Japan. Total loss to shareholders of 76% over the past three years. Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to JP¥455, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Healthcare industry in Japan. Total loss to shareholders of 80% over the past three years. Price Target Changed • Apr 04
Price target decreased by 9.5% to JP¥858 Down from JP¥948, the current price target is an average from 4 analysts. New target price is 107% above last closing price of JP¥415. Stock is down 83% over the past year. The company is forecast to post earnings per share of JP¥61.80 for next year compared to JP¥75.86 last year. New Risk • Mar 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risk High level of debt (54% net debt to equity). Announcement • Mar 24
Amvis Holdings, Inc.(TSE:7071) dropped from FTSE All-World Index (USD) Amvis Holdings, Inc.(TSE:7071) dropped from FTSE All-World Index (USD) Announcement • Mar 19
Amvis Holdings, Inc. to Report Q2, 2025 Results on May 08, 2025 Amvis Holdings, Inc. announced that they will report Q2, 2025 results on May 08, 2025 Reported Earnings • Feb 07
First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2025 results: EPS: JP¥13.78 (down from JP¥18.54 in 1Q 2024). Revenue: JP¥11.8b (up 24% from 1Q 2024). Net income: JP¥1.35b (down 26% from 1Q 2024). Profit margin: 11% (down from 19% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 37%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to JP¥769, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Healthcare industry in Japan. Total loss to shareholders of 62% over the past three years. Reported Earnings • Dec 31
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: JP¥75.86 (up from JP¥64.44 in FY 2023). Revenue: JP¥42.5b (up 33% from FY 2023). Net income: JP¥7.44b (up 18% from FY 2023). Profit margin: 18% (down from 20% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.1%. Earnings per share (EPS) also missed analyst estimates by 3.8%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Announcement • Dec 14
Amvis Holdings, Inc. to Report Q1, 2025 Results on Feb 06, 2025 Amvis Holdings, Inc. announced that they will report Q1, 2025 results on Feb 06, 2025 Major Estimate Revision • Dec 12
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from JP¥54.6b to JP¥53.9b. EPS estimate also fell from JP¥74.28 per share to JP¥66.69 per share. Net income forecast to shrink 12% next year vs 9.4% growth forecast for Healthcare industry in Japan . Consensus price target down from JP¥1,703 to JP¥1,490. Share price fell 6.5% to JP¥801 over the past week. Major Estimate Revision • Nov 26
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from JP¥55.7b to JP¥54.6b. EPS estimate also fell from JP¥85.53 per share to JP¥74.28 per share. Net income forecast to shrink 2.3% next year vs 9.4% growth forecast for Healthcare industry in Japan . Consensus price target of JP¥1,703 unchanged from last update. Share price fell 12% to JP¥893 over the past week. Buy Or Sell Opportunity • Nov 18
Now 20% overvalued Over the last 90 days, the stock has fallen 61% to JP¥1,003. The fair value is estimated to be JP¥832, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 32% over the last 3 years. Earnings per share has grown by 32%. For the next 3 years, revenue is forecast to grow by 17% per annum. Earnings are also forecast to grow by 7.8% per annum over the same time period. Announcement • Nov 12
Amvis Holdings, Inc. (TSE:7071) announces an Equity Buyback for 400,000 shares, representing 0.41% for ¥520 million. Amvis Holdings, Inc. (TSE:7071) announces a share repurchase program. Under the program, the company will repurchase up to 400,000 shares, representing 0.41% of its issued share capital, for ¥520 million. The purpose of the buyback is to enhance shareholder returns and use the stock as an incentive for executives and employees. The program will expire on January 31, 2025. As of September 30, 2024, the company had 97,859,144 ordinary shares in issue (excluding treasury stock) and 252,856 ordinary shares in treasury. Price Target Changed • Nov 09
Price target decreased by 8.2% to JP¥2,655 Down from JP¥2,893, the current price target is an average from 4 analysts. New target price is 75% above last closing price of JP¥1,514. Stock is down 50% over the past year. The company is forecast to post earnings per share of JP¥93.80 for next year compared to JP¥75.86 last year. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to JP¥1,514, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Healthcare industry in Japan. Total loss to shareholders of 39% over the past three years. Announcement • Nov 07
Amvis Holdings, Inc., Annual General Meeting, Dec 20, 2024 Amvis Holdings, Inc., Annual General Meeting, Dec 20, 2024. New Risk • Nov 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (44% net debt to equity). Share price has been volatile over the past 3 months (7.8% average weekly change). New Risk • Sep 21
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥4.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 25 December 2024. Payout ratio is a comfortable 4.2% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Japanese dividend payers (3.8%). Lower than average of industry peers (2.3%). Announcement • Sep 18
Amvis Holdings, Inc. (TSE:7071) announces an Equity Buyback for 250,000 shares, representing 0.3% for ¥500 million. Amvis Holdings, Inc. (TSE:7071) announces a share repurchase program. Under the program, the company will repurchase up to 250,000 shares, representing 0.3% of its issued share capital, for ¥500 million. The program will expire on October 31, 2024. Announcement • Sep 03
Amvis Holdings, Inc. to Report Fiscal Year 2024 Results on Nov 07, 2024 Amvis Holdings, Inc. announced that they will report fiscal year 2024 results on Nov 07, 2024 Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to JP¥2,257, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Healthcare industry in Japan. Total returns to shareholders of 12% over the past three years. Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to JP¥2,450, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 16x in the Healthcare industry in Japan. Total returns to shareholders of 55% over the past three years. Announcement • Jun 06
Amvis Holdings, Inc. to Report Q3, 2024 Results on Aug 08, 2024 Amvis Holdings, Inc. announced that they will report Q3, 2024 results on Aug 08, 2024 Reported Earnings • May 11
Second quarter 2024 earnings released: EPS: JP¥20.17 (vs JP¥17.01 in 2Q 2023) Second quarter 2024 results: EPS: JP¥20.17 (up from JP¥17.01 in 2Q 2023). Revenue: JP¥10.1b (up 34% from 2Q 2023). Net income: JP¥1.98b (up 19% from 2Q 2023). Profit margin: 20% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • May 09
Now 22% overvalued Over the last 90 days, the stock has fallen 16% to JP¥2,183. The fair value is estimated to be JP¥1,787, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Earnings per share has grown by 43%. For the next 3 years, revenue is forecast to grow by 21% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Announcement • Mar 06
Amvis Holdings, Inc. to Report Q2, 2024 Results on May 09, 2024 Amvis Holdings, Inc. announced that they will report Q2, 2024 results on May 09, 2024 Price Target Changed • Feb 21
Price target decreased by 7.6% to JP¥3,290 Down from JP¥3,560, the current price target is an average from 4 analysts. New target price is 32% above last closing price of JP¥2,486. Stock is down 26% over the past year. The company is forecast to post earnings per share of JP¥75.46 for next year compared to JP¥64.44 last year. Reported Earnings • Feb 10
First quarter 2024 earnings released: EPS: JP¥18.54 (vs JP¥14.29 in 1Q 2023) First quarter 2024 results: EPS: JP¥18.54 (up from JP¥14.29 in 1Q 2023). Revenue: JP¥9.54b (up 31% from 1Q 2023). Net income: JP¥1.82b (up 30% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to JP¥2,567, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 18x in the Healthcare industry in Japan. Total returns to shareholders of 93% over the past three years. Announcement • Dec 28
Amvis Holdings, Inc. to Report Q1, 2024 Results on Feb 08, 2024 Amvis Holdings, Inc. announced that they will report Q1, 2024 results on Feb 08, 2024 Announcement • Nov 11
Amvis Holdings, Inc., Annual General Meeting, Dec 22, 2023 Amvis Holdings, Inc., Annual General Meeting, Dec 22, 2023. Reported Earnings • Nov 10
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: JP¥64.44 (up from JP¥44.02 in FY 2022). Revenue: JP¥32.0b (up 39% from FY 2022). Net income: JP¥6.31b (up 48% from FY 2022). Profit margin: 20% (up from 19% in FY 2022). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 5.6%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 47% per year whereas the company’s share price has increased by 50% per year. Price Target Changed • Oct 31
Price target decreased by 10.0% to JP¥3,583 Down from JP¥3,980, the current price target is an average from 4 analysts. New target price is 40% above last closing price of JP¥2,557. Stock is down 13% over the past year. The company is forecast to post earnings per share of JP¥61.00 for next year compared to JP¥44.02 last year. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to JP¥2,127, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 19x in the Healthcare industry in Japan. Total returns to shareholders of 179% over the past three years. Announcement • Oct 01
Amvis Holdings, Inc. to Report Fiscal Year 2023 Results on Nov 09, 2023 Amvis Holdings, Inc. announced that they will report fiscal year 2023 results on Nov 09, 2023 Upcoming Dividend • Sep 21
Upcoming dividend of JP¥3.00 per share at 0.1% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 26 December 2023. Payout ratio is a comfortable 5.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Japanese dividend payers (3.3%). Lower than average of industry peers (2.1%). Reported Earnings • Aug 10
Third quarter 2023 earnings released: EPS: JP¥15.84 (vs JP¥11.00 in 3Q 2022) Third quarter 2023 results: EPS: JP¥15.84 (up from JP¥11.00 in 3Q 2022). Revenue: JP¥8.26b (up 37% from 3Q 2022). Net income: JP¥1.55b (up 45% from 3Q 2022). Profit margin: 19% (up from 18% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Jul 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (5.1% average weekly change). Announcement • May 28
Amvis Holdings, Inc. to Report Q3, 2023 Results on Aug 09, 2023 Amvis Holdings, Inc. announced that they will report Q3, 2023 results on Aug 09, 2023 Buying Opportunity • May 24
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be JP¥3,697, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 43% over the last 3 years. Earnings per share has grown by 52%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Reported Earnings • May 14
Second quarter 2023 earnings released: EPS: JP¥17.01 (vs JP¥10.04 in 2Q 2022) Second quarter 2023 results: EPS: JP¥17.01 (up from JP¥10.04 in 2Q 2022). Revenue: JP¥7.48b (up 40% from 2Q 2022). Net income: JP¥1.67b (up 71% from 2Q 2022). Profit margin: 22% (up from 18% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 53% per year. Buying Opportunity • Apr 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be JP¥3,701, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 44% over the last 3 years. Earnings per share has grown by 54%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Buying Opportunity • Mar 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 8.7%. The fair value is estimated to be JP¥3,702, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 44% over the last 3 years. Earnings per share has grown by 54%. For the next 3 years, revenue is forecast to grow by 24% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Reported Earnings • Feb 12
First quarter 2023 earnings released: EPS: JP¥14.29 (vs JP¥10.42 in 1Q 2022) First quarter 2023 results: EPS: JP¥14.29 (up from JP¥10.42 in 1Q 2022). Revenue: JP¥7.26b (up 44% from 1Q 2022). Net income: JP¥1.40b (up 38% from 1Q 2022). Profit margin: 19% (in line with 1Q 2022). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 54% per year whereas the company’s share price has increased by 51% per year. Price Target Changed • Feb 10
Price target increased by 8.0% to JP¥3,805 Up from JP¥3,523, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of JP¥3,630. Stock is up 79% over the past year. The company is forecast to post earnings per share of JP¥58.02 for next year compared to JP¥44.02 last year. Announcement • Dec 11
Amvis Holdings, Inc. to Report Q1, 2023 Results on Feb 09, 2023 Amvis Holdings, Inc. announced that they will report Q1, 2023 results on Feb 09, 2023 Price Target Changed • Nov 16
Price target increased to JP¥3,448 Up from JP¥3,188, the current price target is an average from 4 analysts. New target price is 12% above last closing price of JP¥3,070. Stock is up 11% over the past year. The company is forecast to post earnings per share of JP¥58.18 for next year compared to JP¥88.04 last year. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Nov 12
Amvis Holdings, Inc., Annual General Meeting, Dec 23, 2022 Amvis Holdings, Inc., Annual General Meeting, Dec 23, 2022. Reported Earnings • Nov 12
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: JP¥88.04 (up from JP¥28.07 in FY 2021). Revenue: JP¥23.1b (up 51% from FY 2021). Net income: JP¥4.28b (up 63% from FY 2021). Profit margin: 19% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) also surpassed analyst estimates by 109%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Healthcare industry in Japan. Over the last 3 years on average, earnings per share has increased by 70% per year whereas the company’s share price has increased by 73% per year. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improved over the past week After last week's 17% share price gain to JP¥2,838, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 12x in the Healthcare industry in Japan. Total returns to shareholders of 426% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at JP¥2,802 per share. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥6.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 27 December 2022. Payout ratio is a comfortable 5.6% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (2.2%). Buying Opportunity • Sep 15
Now 21% undervalued Over the last 90 days, the stock is up 62%. The fair value is estimated to be JP¥6,344, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Earnings per share has grown by 56%. For the next 3 years, revenue is forecast to grow by 23% per annum. Earnings is also forecast to grow by 25% per annum over the same time period. Price Target Changed • Sep 13
Price target increased to JP¥6,233 Up from JP¥5,457, the current price target is an average from 4 analysts. New target price is 18% above last closing price of JP¥5,270. Stock is up 31% over the past year. The company is forecast to post earnings per share of JP¥83.10 for next year compared to JP¥56.14 last year. Announcement • Sep 01
Amvis Holdings, Inc. to Report Fiscal Year 2022 Results on Nov 10, 2022 Amvis Holdings, Inc. announced that they will report fiscal year 2022 results on Nov 10, 2022 Reported Earnings • Aug 12
Third quarter 2022 earnings released: EPS: JP¥21.99 (vs JP¥14.45 in 3Q 2021) Third quarter 2022 results: EPS: JP¥21.99 (up from JP¥14.45 in 3Q 2021). Revenue: JP¥6.02b (up 48% from 3Q 2021). Net income: JP¥1.07b (up 54% from 3Q 2021). Profit margin: 18% (in line with 3Q 2021). Over the next year, revenue is forecast to grow 33%, compared to a 4.6% growth forecast for the industry in Japan. Valuation Update With 7 Day Price Move • Jul 26
Investor sentiment improved over the past week After last week's 15% share price gain to JP¥4,955, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 57% over the past year. Simply Wall St's valuation model estimates the intrinsic value at JP¥7,902 per share. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment deteriorated over the past week After last week's 20% share price decline to JP¥3,360, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 13x in the Healthcare industry in Japan. Total returns to shareholders of 4.6% over the past year. Announcement • May 29
Amvis Holdings, Inc. to Report Q3, 2022 Results on Aug 10, 2022 Amvis Holdings, Inc. announced that they will report Q3, 2022 results on Aug 10, 2022 Valuation Update With 7 Day Price Move • May 19
Investor sentiment deteriorated over the past week After last week's 16% share price decline to JP¥3,900, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 14x in the Healthcare industry in Japan. Total returns to shareholders of 15% over the past year. Simply Wall St's valuation model estimates the intrinsic value at JP¥4,614 per share. Reported Earnings • May 15
Second quarter 2022 earnings: EPS exceeds analyst expectations Second quarter 2022 results: EPS: JP¥20.08 (up from JP¥12.12 in 2Q 2021). Revenue: JP¥5.35b (up 53% from 2Q 2021). Net income: JP¥975.0m (up 76% from 2Q 2021). Profit margin: 18% (up from 16% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.0%. Over the next year, revenue is forecast to grow 34%, compared to a 5.0% growth forecast for the industry in Japan. Price Target Changed • Apr 27
Price target increased to JP¥6,000 Up from JP¥4,900, the current price target is an average from 3 analysts. New target price is 21% above last closing price of JP¥4,945. Stock is up 55% over the past year. The company is forecast to post earnings per share of JP¥77.49 for next year compared to JP¥56.14 last year. 
